Peptide injections: Does injection site actually change how they work?

What did @zacsmithfitness actually say?

The creator made two distinct claims. First, that injection route (intramuscular vs. subcutaneous) "doesn't matter" for peptides, with the only difference being a "fast revolve rate" with IM injection. Second, he personally mixes his peptides and testosterone into the same syringe for a single daily IM shot, arguing that subcutaneous oil injections cause lumps and pain.

To his credit, he frames the testosterone-mixing practice as a personal preference, not a universal recommendation. He even invites debate in the comments. That's an unusually honest qualifier for TikTok. But "it doesn't matter" is doing a lot of heavy lifting here, and the mixing claim deserves more scrutiny than a casual aside.

Does the science back this up?

Partly. Absorption kinetics do differ between IM and subcutaneous routes, but calling it irrelevant oversimplifies a real pharmacological distinction. The mixing claim has almost no published support and carries legitimate compatibility concerns.

Subcutaneous injection generally produces slower, more sustained absorption due to lower vascularity in adipose tissue. Intramuscular injection reaches systemic circulation faster because muscle is more vascularized. For peptides like BPC-157 or ipamorelin, this difference may affect peak plasma concentration and, theoretically, receptor saturation timing. A 2018 review by Lau et al. in Drug Delivery confirmed that route of administration meaningfully alters pharmacokinetic profiles for peptide-based therapeutics. Whether that difference is clinically significant for unregulated peptide use is genuinely unknown, because most of these compounds lack robust human pharmacokinetic data to begin with.

On the testosterone-mixing question: oil-based testosterone esters and aqueous peptide solutions are chemically incompatible in a meaningful sense. When you draw them into the same syringe, you get an emulsion, not a true solution. Precipitation of the peptide is a real risk, potentially reducing efficacy or altering the injection experience.

What did they get wrong (or right)?

He got the general direction right on subcutaneous oil injections causing lumps. That's a well-documented injection site reaction with oil-based androgens, and moving to IM does reduce it for most users. That part is reasonable practical experience.

He got the "doesn't matter" claim wrong, or at least stated it far too broadly. Route of administration is one of the foundational variables in pharmacokinetics. Saying it doesn't matter because the difference is just "revolve rate" (presumably meaning absorption rate) is actually conceding the point while dismissing it. Absorption rate matters. It affects how much peptide reaches target tissue, when it peaks, and potentially how long it remains active.

The syringe-mixing practice is the part that should raise flags. Mixing a lipophilic oil-based compound with a hydrophilic aqueous peptide solution creates an unstable preparation. There is no peer-reviewed evidence supporting this as a safe or effective practice. Compounding pharmacies do not produce pre-mixed oil-and-peptide formulations for a reason. Users doing this at home have no way to verify uniform distribution, stability, or sterility of the resulting mixture.

What should you actually know?

If you are using peptides under medical supervision, the injection route should be part of your prescriber's protocol, not a personal preference borrowed from a fitness creator. Different peptides may have different clinically preferred routes based on their molecular weight, stability, and intended effect.

• Subcutaneous injection is the standard recommended route for most research and compounded peptides, including BPC-157 and ipamorelin, based on manufacturer guidance and prescriber protocols.
• Intramuscular injection is faster for absorption but is not universally better. Faster is not the same as more effective.
• Mixing oil-based and water-based injectables in the same syringe is not a validated practice. It introduces stability and sterility variables that cannot be controlled in a home setting.
• Injection site reactions from subcutaneous testosterone are real, but the solution is typically technique adjustment or prescribed formulation changes, not self-directed route switching.
• Anyone injecting peptides should be doing so under the guidance of a licensed provider who can assess their specific situation, not based on TikTok comment-section debates.